What 2013 Has in Store for Johnson & Johnson

As of a few days ago, Johnson & Johnson's  (NYSE: JNJ  )  stock price was up by 6.7% for 2012. Over that same time frame, the Dow Jones Industrial Average (DJINDICES: ^DJI  ) was up 7.55%. Back in September, I predicted that Johnson & Johnson wouldn't beat the market, but since then the stock price rose 5.15% while the S&P 500  (SNPINDEX: ^GSPC  ) climbed only 1.33%. The past few months, a number of events have taken place that could have changed my opinion on Johnson & Johnson. Read on, and I'll reveal my prediction moving into 2013. 

The past few years have been tough for the company, as it's been plagued with product recalls. I recently noted that in 2012 J&J had a product recall nearly once a month. That opened the door for generic brands to step in and take market share from the once-dominant industry leader. Worse still, some consumers no longer trusted the safety of J&J's products, and a number of investors no longer believed the company was a viable long-term holding.

When Warren Buffett dumped nearly his entire stake in J&J, not only did the share price take a hit for days after the announcement, but the long-term effects will also be felt during 2013 and perhaps beyond. Long-term value-oriented shareholders like Buffett probably won't even give J&J a chance in 2013 simply because Buffett sold the stock just a few months ago, given than Buffett is known as an investor who will hold a stock not for months or even years, but decades. With few catalysts for the stock, losing the value investing crowd is likely to dampen the stock's price appreciation in the coming months.

But one catalyst that our health-care industry analyst here at the Fool believes will propel the stock in 2013 is the fall of robotic medical devices. With Affordable Care Act laws starting to go into effect within the coming weeks, and higher taxes on the sale of medical devices as part of the law, many investors believe companies such as MAKO Surgical  (UNKNOWN: MAKO.DL  ) and Intuitive Surgical  (NASDAQ: ISRG  )  will take big hits in 2013. If these cutting-edge medical-device makers slide in the coming year, it's believed that J&J will jump in and take some of the business. Some analysts think that the lower price points of J&Js older, more traditional surgical devices will make them popular choices in the year ahead.

Whether or not higher taxes on medical devices push the new technology out of the reach of the mainstream medical community in 2013, the stage is already set, and eventually, whichever medical device is safer for the patient will be the one that ultimately wins the battle. But I also believe that the industry has room for all three companies in the future, whether they remain as separate competitors or join in some kind of an alliance to maximize profits.

Foolishly investing
Although the S&P 500 has lost to Johnson & Johnson since September, I believe the index will beat the stock over the next few years. But I will remain a proud shareholder during that time. Even with all the product recalls over the past few years, J&J is a company that was built to last the test of time. You may not beat the market owning the stock during the next few years, but you will certainly sleep better at night knowing that the stock is much less volatile than the overall market. 

To learn more about Johnson & Johnson, keep reading by getting your free copy of our premium research report to find out if J&J is a well-diversified giant that's perfect for your portfolio. Make sure you understand the full story behind the stock, along with its key opportunities and risks, by claiming your copy today. Simply click here now for instant access.


Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 03, 2013, at 6:55 PM, megaroid wrote:

    I think this is a bit misleading as the effect of ISRG, and especially Mako are insignificant to earnings etc. The ISRG space and DePuy space compete, a bit. DePuy does much more than ISRG surgical space. Therefore, I think robotic ups and downs is not material to J&J billions in revenue, and the delta in the business marketshare change unnoticable to even the best analysts.

    However, J&J must prove operational excellence. The risk of legal losses from sloppy operations in J&J's medical field is the big drag. Buffet will NOT stand for this risk of mismanagement. Without radical change it will take time for J&J to reestablish credibility. Hence the stock will underperform. I don't own it and won't buy it until all of this is history. I can go elsewhere for similiar returns with less risk.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2174275, ~/Articles/ArticleHandler.aspx, 12/19/2014 4:57:33 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement